INSIGHTS ON CLINICAL TRIAL PARTNERING
-
![The US Biosimilar Approval Pathway: Policy Precedes Science - A Regulatory Perspective]( "Why Legacy RTSM Systems Create Risk in Biosimilar Trials")
Why Legacy RTSM Systems Create Risk in Biosimilar TrialsLearn how real-time visibility, adaptive supply planning, and proactive risk management can reduce waste and improve study execution.
-
![GettyImages-2192289495-caner-patient-family-support-care]( "Rethinking Trial Access Through Trust-Driven Design And Local Collaboration")
Rethinking Trial Access Through Trust-Driven Design And Local CollaborationLocally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.
-
![GettyImages-1413755087-business-man-computer-data-workflow-automation]( "Biopharma Giant Streamlines Infrastructure With Proprietary Software")
Biopharma Giant Streamlines Infrastructure With Proprietary SoftwareArchiving legacy QMS systems into a centralized platform reduced costs, simplified access, and improved efficiency for a global diagnostics company undergoing quality process harmonization.
-
![GettyImages-1371925389-lab-scientist-collaboration-computer-clipboard]( "Navigating Complexity In Master Protocols With Key Operational Partners")
Navigating Complexity In Master Protocols With Key Operational PartnersComplex adaptive trials offer real efficiency gains, but success hinges on having experienced partners to manage the operational details.
-
The Hidden Cost Of Preferred Vendors10/21/2025
Familiar vendors offer comfort — but at the cost of innovation, fit, and fresh thinking. Ease shouldn’t outweigh excellence when selecting partners for your clinical trial.
-
Clinical Trial Payments At Scale: Volume And Control2/4/2026
Find an operational explanation of what payment scale actually means in clinical trials, why small-study approaches break down, and how volume reshapes compliance, reporting, and automation decisions.
-
Breaking Down Early Small Molecule Development3/11/2026
Adopt an integrated development strategy to streamline the path from early development to the clinic, ensuring timely clinical supply while reducing delays, risk, and inefficiencies.
-
Why The TrialKit Platform License Agreement Changes The Economics Of Clinical Trials2/24/2026
A platform‑based pricing model removes change‑order friction, enabling predictable budgets and faster study adjustments. It supports operational agility and portfolio‑level efficiency as trials evolve.
-
Leveraging Functional Service Providers For Drug Development Efficiency8/5/2025
Discover how functional service providers (FSPs) are reshaping clinical research by offering specialized expertise, flexible resources, and cost-effective solutions.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
![Eye Drop iStock-1182318206]( "Comprehensive Services For Ophthalmology Drug Development")
As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions can support your program from lead candidate selection to market.
-
![GettyImages-1331910730 payment]( "Why IQVIA Participant Payments?")
Learn about how this participant-friendly technology ensures efficient and secure payments, enhancing the clinical trial experience for all involved.
-
![GettyImages-953782406-digital-patients-people-recruit]( "Subject Eligibility Review: Enrolling The Right Subjects")
Screen failures, dropouts, and protocol deviations start with the wrong participants. A holistic eligibility review process helps get enrollment right the first time.
-
![EU Regulations, europe union flag-GettyImages-1175944437]( "EU Clinical Trial Compliance: De-Risking CTR & CTIS")
This essential guide walks through mastering the complex landscape of clinical trial regulations, providing a clear, practical breakdown of regulatory timelines, legal obligations, and more.
-
![clinical-sites-GettyImages-2057440780]( "A Premier Site Network For High-Performance Trials")
A national research network with advanced facilities, expert investigators, and diverse patients to support efficient Phase I–IV trials and speed complex protocols and enrollment.
